

## **Prematurely ended - Statement**

<b>EudraCT Number:</b>	2007-003642-15
<b>Full title of the study:</b>	A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects (ITP-BAFF)
<b>Sponsor-Code:</b>	Belimumab bei ITP
<b>Sponsor:</b>	Charité – Universitätsmedizin Berlin
<b>Principal Investigator/ Study Contact::</b>	Prof. Dr. Abdulgabar Salama/ Dr. Florian Emmerich Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Institut für Transfusionsmedizin, Augustenburger Platz 1, 13353 Berlin <a href="mailto:abdulgabar.salama@charite.de">abdulgabar.salama@charite.de</a>
<b>Product:</b>	Belimumab (LyphoStat-B-TM Antibody)
<b>Date of early termination:</b>	2008/11/03
<b>Statement:</b>	Due to difficulties in recruitment and change of employer of the principal investigator in October 2008, no patient was enrolled in the study. The cooperation agreement between the financial sponsor of the above-mentioned study, Human Genome Science GmbH, and the sponsor representative of Charité was therefore terminated on November 3, 2008.